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patients’ lifetimes. Duration of treatment was assumed to be 5 years, before switching 
to a basal insulin regimen. Changes were made to the base-case assumptions. First, 
the utility change per BMI unit gained (in patients with a BMI > 25 kg/m2) was 
decreased from −0.01 to −0.0061. Second, the treatment duration was increased from 
5 to 10 years. All other variables were kept constant. RESULTS: In the comparison 
with rosiglitazone, liraglutide was associated with a base-case incremental cost-effec-
tiveness ratio (ICER) of £6226 per QALY gained, which increased to £7545 with BMI 
utility changes and to £16,477 when the treatment duration was increased. Similar 
increases were seen for comparisons with glimepiride (£13,257 (base case) to £25,343 
(BMI utility change) and £38,368 (10-year treatment)) and sitagliptin (£9,851 [base 
case] to £14,616 [BMI changes] and £17,089 [10-year treatment]). CONCLUSIONS: 
Increasing the treatment duration and decreasing the impact of BMI on quality of life 
increased the ICER of liraglutide versus comparators. Liraglutide was shown to be 
cost-effective in dual therapy (assuming a threshold of £20,000 per QALY gained) 
versus rosiglitazone and sitagliptin in all three scenarios (base case, BMI utility 
changes, and 10-year treatment).
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OBJECTIVES: Analysis of the post-interventional follow-up of the UKPDS found that 
the beneﬁ ts of intensive therapy persisted even 10 years after the trial, a ﬁ nding 
consistent with “metabolic memory” (i.e., early metabolic status inﬂ uences long-term 
outcomes). We assessed the potential impact of “metabolic memory” on the cost-
effectiveness of intensive versus conventional care in Sweden. METHODS: We used 
the Economic and Health Outcomes (ECHO)-T2DM model to simulate lifetime health 
outcomes (including QALYs) and medical costs for 500 cohorts of 2000 newly diag-
nosed patients. In each cohort, patients were randomized to intensive or conventional 
care and HbA1c treatment effects corresponding to the UKPDS study were applied 
for the ﬁ rst 10 years. Consistent with ﬁ ndings from the follow-up study, HbA1c values 
were assumed to converge by year 10. Subsequently, in the intensive care arm, “meta-
bolic memory” effects (reduced risk for certain microvascular and macrovascular 
events and mortality) were applied. Two sets of “metabolic memory” effects from the 
UKPDS follow-up study were used: those observed in the sulfonylurea/insulin sub-
sample and those observed in the metformin subsample. a scenario assuming no 
“metabolic memory” effects was simulated for comparison. Unit costs were derived 
from the Swedish literature (modeling studies and a regression analysis of inpatient 
care costs based on administrative hospital data linked to the Swedish National 
Diabetes Register). RESULTS: Including “metabolic memory” had a large effect on 
the cost-effectiveness estimates. The incremental cost-effectiveness ratio declined from 
SEK2,387,292 (~c250,000) without “metabolic memory” to SEK731,308 (~c75,000) 
assuming effects from the sulfonylurea/insulin sample and to SEK445,425 (~c45,000) 
assuming effects from the metformin sample. CONCLUSIONS: These results suggest 
that good glycemic control early in the disease continuum may confer signiﬁ cant 
medical cost savings over the long term. Evaluations of the cost-effectiveness of 
intensive glycemic control in newly diagnosed patients should potentially consider the 
health and cost consequences of “metabolic memory.”
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OBJECTIVES: This study aimed to assess cost-effectiveness of treatment with liraglu-
tide added to a standard therapy with metformin (MET) or/and sulphonylurea (SU) 
compared with rosiglitazone and exenatide. METHODS: Our study used a health 
economic model (the CORE Diabetes Model) to project the long-term costs and clini-
cal outcomes of liraglutide based on clinical data from LEAD-1 trial: liraglutide + SU 
versus rosiglitazone + SU; and LEAD-6 trial: liraglutide + MET+/−SU versus exenatide 
+ MET+/−SU. The analysis was performed from the Slovak health-care services payer’s 
perspective in a 20-year time horizon. The analysis used health-state utility values 
from published sources to assess the effect of treatment on QALYs. The unit costs of 
treatment and complications were derived from published sources and ofﬁ cial tariff 
lists for health-care services paid by public payer. All ﬁ gures are shown in EUR. 
RESULTS: QALYs increased with liraglutide 1.2 mg + SU versus SU + rosiglitazone 
4 mg by 0.203. Total costs increased by c2561 resulting in incremental costs per 
QALY of c12,615. The incremental cost-effectiveness ratio for liraglutide 1.8 mg + 
MET+/−SU versus exenatide 10 μg + MET+/−SU was estimated at c24,013 per QALY 
gained (QALYs increased by 0.112). CONCLUSIONS: Using the CORE Diabetes 
Model and data from the LEAD 1 and LEAD 6 trials treatment with liraglutide is a 
cost-effective intervention compared with both rosiglitazone and exenatide. Sensitivity 
analysis showed the results are only moderately changing when altering the key 
parameters and assumptions.
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BACKGROUND: Unlike most other antihyperglycemic drugs, glucagon-like peptide 
1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. 
In a randomized clinical trial (RCT) over 26 weeks reported by Buse et al. (2009), the 
novel GLP-1 agonist liraglutide (1.8 mg once daily, OD) was found to be signiﬁ cantly 
more effective than exenatide (10 μg twice daily) in terms of HBA1c reduction. 
OBJECTIVES: To compare, from a German payer’s (SHI) perspective, the long-term 
clinical and cost-effectiveness of liraglutide (1.8 mg OD) versus exenatide (10 μg BID) 
in T2D patients, based on data from the randomized clinical trial (RCT) by Buse et 
al. 2009. METHODS: The CORE Diabetes Model (CDM) was applied using RCT 
data. The model was calibrated to RCT baseline characteristics and background 
mortality in a German diabetes population, applying epidemiological data from long-
term studies including UKPDS and Framingham to project morbidity and mortality 
of T2DM. Unit costs for direct costs were applied from an SHI perspective for year 
2009. a discounting rate of 3% was used for costs and clinical effects. For hypothetical 
cohorts of 1000 patients, each followed for 20 years, patients were assumed to be 
maintained on liraglutide and exenatide, respectively, for 5 years and subsequently 
switched to insulin. Costs and effects were projected over a 20-year time horizon. 
RESULTS: Estimated 20-year survival rates were higher for liraglutide 1.8 mg once 
daily (36.8%) compared to exenatide 10 μg administered twice daily (35.6%), and 
cumulative costs were c46,308 (liraglutide) and c45,025 (exenatide), respectively. 
Base-case ICERs were c16,632 per life-year gained for liraglutide versus exenatide, 
and c11,606 for liraglutide versus exenatide per QALY gained. Sensitivity analyses 
indicated robustness of ﬁ ndings. CONCLUSIONS: Long-term projections combining 
RCT data with the CDM strongly suggest an acceptable to attractive cost-effectiveness 
of liraglutide compared to exenatide according to currently prevailing standards.
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OBJECTIVES: To assess the long-term cost-effectiveness of treatment with liraglutide on 
top of standard therapy with metformin (MET) compared with sulphonylurea (SU) in 
people with type 2 diabetes. METHODS: The extensively published and validated CORE 
Diabetes Model was populated with the clinical data from LEAD 2: liraglutide + MET 
versus SU + MET. The analysis was performed from the polish health-care services payer’s 
perspective. a 20-year time horizon was chosen to reﬂ ect the costs and outcomes of dia-
betes as these are often only seen in the later stages of the disease. The analysis used 
health-state utility values from published sources to assess the effect of treatment on 
QALYs. The unit costs of treatment and complications were derived from published 
sources or based on expert opinion survey and Polish ofﬁ cial tariff lists for health-care 
services paid by public payer. All ﬁ gures are shown in EURO (1 EURO = 3.9 PLN). 
RESULTS: QALYs increased with liraglutide 1.2 mg + MET versus SU + MET by 0.191. 
Total costs increased by c3,349 resulting in incremental costs per QALY of c17,565. The 
incremental cost-effectiveness ratio for liraglutide 1.8 mg + MET versus SU + MET was 
estimated at c24,842 per QALY gained (QALYs increased by 0.207). Sensitivity analysis 
showed the results to be moderately changing when altering the key parameters and 
assumptions (for liraglutide 1.2 mg range from 12,944 to c30,275/QALY). CONCLU-
SIONS: Treatment with liraglutide is a cost-effective intervention compared with sulpho-
nylurea and is likely to represent good value for money in Polish setting.
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OBJECTIVES: This study evaluates the long-term economic consequences of saxagliptin 
versus sulfonylurea (SU, glipizide) as second-line therapy when used in combination with 
metformin (MET) after failure of monotherapy treatment with MET, in patients with 
type 2 diabetes mellitus (T2DM) in Germany. METHODS: A published discrete event 
simulation model with a ﬁ xed time increment was used and set to a 40-year (life-) time 
horizon. Disease progression was modeled using evidence from the UK Prospective 
Diabetes Study (UKPDS 68). The treatment sequence matched that of published guide-
lines, and efﬁ cacy and safety data were derived from published sources. The model 
assumes that quality-adjusted life-years (QALYs) are affected by complications and 
hypoglycaemic events over a lifetime. As such costs and utility decrements for macro- 
and micro-vascular complications, and adverse events such as severe hypoglycaemia are 
included. Costs were speciﬁ c to the German setting where SUs are generic. Costs and 
effects were discounted annually at 3%. The perspective of the national sick funds was 
taken, and recommendations from the Institute for Quality and Efﬁ ciency in Health 
Care (IQWiG) were considered. RESULTS: Treatment with saxagliptin + MET was 
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associated with lower incidence of both symptomatic and severe hypoglycaemic events, 
resulting in an incremental beneﬁ t of 0.12 QALYs and an incremental cost-effectiveness 
ratio (ICER) of c13,931 per QALY gained. Modest reductions in all macro-vascular 
and micro-vascular complications were seen in those receiving saxagliptin + MET 
compared with SU + MET. Sensitivity analysis showed that treatment-related weight 
changes, as a risk factor for complications, represent the most inﬂ uential driver of cost-
effectiveness. CONCLUSIONS: Saxagliptin is associated with improved outcomes, a 
lower incidence of hypoglycaemic events, and weight neutrality, when compared with 
generic SU, at a cost that would likely be considered acceptable in the German setting.
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OBJECTIVES: Saxagliptin is indicated as an add-on combination therapy for adult 
patients with diabetes mellitus type 2 (T2D) to improve glycaemic control in combina-
tion with metformin, a sulphonylurea (SU) or a thiazolidinedione (TZD). The objective 
of this study was to evaluate the cost-effectiveness in Spain of saxagliptin when added 
to metformin in comparison with SU plus metformin or TZD plus metformin. 
METHODS: The analysis uses the Cardiff Long Term Model which simulates treatment 
pathways of pharmacological treatment of T2D from initiation of treatment until death. 
Efﬁ cacy and safety data are based on an indirect comparison of saxagliptin and SU and 
TZD based on the similarity in safety and efﬁ cacy between saxagliptin and sitagliptin 
demonstrated in a 18-week non-inferiority study (CV181,056). Available direct com-
parative trials between sitagliptin and TZDs and SUs are used to serve as data sources 
to assign efﬁ cacy and safety parameters. Spanish costs are used as for macro and micro-
vascular complications as well as adverse events such as severe hypoglycemia. Utility 
decrements for ischemic heart disease, myocardial infarction, congestive heart failure, 
stroke, blindness, end-stage renal disease, transplant, amputation and body mass index 
are also accounted in the model. Health outcomes are measured in terms of QALYs, 
assuming that the lifetime QALY is affected by complications, occurrence of hypogly-
caemic episodes and weight changes. The perspective used is that of the Spanish Health 
System. RESULTS: Saxagliptin as add on to metformin is cost-effective compared with 
SU and TZD (ICER < c10,000). Extensive univariate sensitivity analysis shows that the 
most inﬂ uential factor is the weight variation, which increases with treatment with SU 
and TZD whereas DPP-4 inhibitors have shown to be weight neutral. CONCLUSIONS: 
The cost-effectiveness analysis shows that saxagliptin is cost-effective compared with 
both SU and TZD in combination with metformin for the treatment of T2DM in Spain.
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OBJECTIVES: Although having substantial costs, the new antidiabetics for Type 2 
diabetes treatment present more alternatives for glycemic control of the disease. To 
evaluate their cost-effectiveness, the New Antidiabetics for Type 2 diabetes indexed 
on PubMed, EMBASE databases and American Diabetes Association abstracts were 
evaluated. METHODS: The cost-effectiveness of Type 2 diabetes based on the new 
antidiabetics was analyzed through literature review. Searches were carried out in 
PubMed, EMBASE and ADA abstracts to identify the articles published from 2008 
to 2010, keying in the terms “cost-effectiveness” and “type 2 diabetes” with language 
ﬁ ltering, “English.” The language ﬁ lter for “Turkish” was also used but no result was 
achieved. Upon this ﬁ ltration, the abstracts were reviewed to determine whether they 
included antidiabetics. RESULTS: Ten full texts, seven abstracts and three peer 
reviews were identiﬁ ed. In all studies, the cost-effectiveness of antidiabetics was 
assessed using the validated CORE Diabetes Model, except for two based on the 
Discrete Event Simulation Model. The outcomes from IMPROVE, PROactive, 
PRESENT, UKPDS and PREDICTIVE trials were used. In these studies, biphasic 
insulin aspart, exenatide, pioglitazone, insulin detemir, insulin glargine and sitagliptin 
were all studied under different settings and against various comparators. Biphasic 
insulin aspart versus human premix insulin was mostly found to be cost-effective in 
certain studies. Exenatide versus insulin glargine was established to be likely cost-
effective in two studies. Pioglitazone was found to be dominant compared to rosigli-
tazone. Insulin detemir was established to be cost-saving in comparison with OAD or 
NPH insulin, or insulin glargine. Sitagliptin was regarded as either cost-effective or 
cost-saving compared to rosiglitazone. CONCLUSIONS: Different results in terms of 
cost-effectiveness of various antidiabetics under certain settings and against varied 
comparators were achieved. In future, demonstrated gains in QALYs will be found to 
be essential for these antidiabetics to be regarded as cost-effective.
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OBJECTIVES: Continuous glucose monitoring (CGM) has been found to improve 
glycemic control in type 1 diabetes in recent trials. The objective of this study is to 
assess the cost-effectiveness of CGM compared with self-monitoring of blood glucose 
(SMBG) in type 1 diabetes patients, from a societal perspective in the The Netherlands. 
METHODS: The analysis was performed using the CORE Diabetes model with inputs 
for the The Netherlands. Clinical effectiveness of CGM in terms of lowering HbA1c 
was taken from the GuardControl study. Costs of complications and complication-
related days off work were based on data from Erasmus University Rotterdam. Annual 
treatment costs were estimated using cost information from the Healthcare Insurance 
Board. Costs and effects were discounted at 4% and 1.5%, respectively. a lifetime 
horizon (60 years) was adopted for the analysis. a range of sensitivity analyses were 
conducted. RESULTS: The total costs per patient over 60 years for the CGM arm 
were c10,069 (73,348) higher than costs for the SMBG arm. Complication costs were 
lower, and treatment costs were higher for the CGM compared to the SMBG arm. 
Compared to the SMBG arm, 0.463 (3.063) QALYs were gained in the CGM group. 
The cost per QALY gained was c21,731. Probabilistic sensitivity analyses showed that 
this result is robust. CONCLUSIONS: At a willingness to pay threshold of c40,000 
per QALY, CGM appears to be a cost-effective treatment option compared to SMBG 
in patients with type 1 diabetes.
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OBJECTIVES: A multifaceted quality improvement programme for the care of diabe-
tes was implemented in two different Flemish regions (Aalst and Leuven) and with 
slightly different modalities. The overall objective of the programmes was to improve 
adherence to evidence-based guidelines on diabetes in primary care physicians. The 
aim of this study was to assess the cost-effectiveness of the programs compared to 
regular care in both regions. METHODS: Short-term effects of the programmes were 
extrapolated to long-term hard endpoints, using the validated UKPDS Outcomes 
Model, supplemented by two self-developed Markov models to account for beneﬁ ts 
on process parameters (screening for retinopathy and nephropathy). a simulation of 
the evolution of patients was made over a time horizon of 25 years with cycles of 1 
year, from a public health care payer perspective. Cost data of the different disease 
states and extra direct medical costs due to intensiﬁ ed patient management were col-
lected from literature and from the National Institute for Health and Disability Insur-
ance. For the self developed Markov models, utility data for all states were obtained 
from published studies and transition probabilities were obtained from local epide-
miological studies and published trials. In the simulation, the intervention was 
assumed to be implemented three times over the predicted life expectancy. Determin-
istic sensitivity analyses were performed on the combined results of outcome and 
process parameters. RESULTS: At a cost of intervention of c185 (Aalst) and c284 
(Leuven) per patient, the analyses show ICER’S for Aalst and Leuven of respectively 
c15,206.70/QALY and c10,397.96/QALY. Sensitivity analyses show few inﬂ uence of 
changed input variables. CONCLUSIONS: When using a ratio of c30,000/QALY as 
threshold of willingness to pay for health gain, the diabetes health care programmes 
have an acceptable ICER in both regions.
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OBJECTIVES: To analyze the effectiveness and safety of three treatment regimens, 
and to project and compare long-term outcomes and costs of complications of type 2 
diabetes mellitus (T2DM). METHODS: Data of 3678 patients (mean age 49.6 ± 0.19 
years; 47% men; mean diabetes’s duration—6 years) included in “evaluation of dia-
betes mellitus complications” program were taken for mathematic simulation using 
the validated Center for Outcomes Research (CORE) Diabetes Model. Patients were 
randomly divided into three groups: insulin therapy (NovoMix® 30), oral antidiabetic 
drugs (OAD; combination of glibenclamide + metformin in most cases) and diet. Life 
expectancy, cumulative incidence of cardiovascular, ocular events and health care 
costs were estimated over period duration—50 years. RESULTS: Estimated life expec-
tancy was higher in insulin group compared with OAD and diet groups (17.2, 16.5, 
and 16.0 years). The best QALY’s results were also achieved in insulin group (10.7, 
10.2 and 9.9 years) due to decreased rates of myocardial infarction (morbidity/mortal-
ity), decompensated heart failure, ocular complications and diabetic retinopathy. 
Higher direct costs for years of life gained in insulin group (1287, 1203, and 1180 
thousands of rub.) were associated with concomitant decreasing of indirect costs 
(362.7, 382.5, and 381.3 thousands of rub.). The costs for one patient with T2DM 
per 1 year were nearly the same in three groups (95.9, 95.9, and 97.6 thousands of 
rub.). CONCLUSIONS: use of the CORE Diabetes Model life expectancy, diabetes 
complications, and costs favored insulin NovoMix® 30 therapies compared with 
OAD or diet in treatment of T2DM.
